Terumo Gets Its Toe Wet in the US Cardiovascular Market

Terumo is a major device company in Japan, but has to date had little success in building a US business. With the acquisition of 3M's cardiovascular business, is Terumo taking its first major step toward building a greater US presence?

After a breathtaking couple of years during which they drove M&A activity in medical devices to one high after another, cardiovascular device companies, particularly US firms, seem to be taking a rest. With its stock price sagging, Boston Scientific Corp. has been all but out of the deal-making arena for the last year or so. St. Jude Medical Inc. suffers from similar problems. At press time, Johnson & Johnson was negotiating to buy Centocor Inc. , at least in part for its anti-platelet agent, ReoPro, which could prop up its deflated stent business, but which also suggests the company is turning its attention in cardiovascular from devices to drugs. Medtronic Inc. could still play, but after doing $8 billion in acquisitions over eight months in 1998, it's earned a breather. Guidant Corp. has plenty of money and energy—but beyond it, there's hardly a robust list of potential deal-makers.

What about Terumo Corp? The Japanese company's $1.7 billion in annual sales—with a $4 billion market cap—would qualify it as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By 

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.